Linked Life Data

15544482

Source:http://linkedlifedata.com/resource/pubmed/id/15544482

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
21
pubmed:dateCreated
2004-11-16
pubmed:abstractText
Haemoglobinopathies differ in geographic prevalence but together are amongst the most common genetic disorders worldwide. Despite huge diagnostic progress, therapeutic options remain limited, with many treatments still at the experimental stage, no more so than in pregnancy: not only does the presence of a fetus subject treatments to greater limitations, but also any worsening of the anaemia as pregnancy progresses results in higher fetomaternal morbidity and mortality. Anaemia weakens the response to peripartum blood loss, with the risk of postpartum complications. Until recently the standard conventional therapy for severe anaemia was (repeated) blood transfusion, with its well-known risks. Recombinant human erythropoietin (rhEPO) can induce fetal haemoglobin and is a safer, if less immediately effective, alternative for the correction of anaemia in pregnant patients with haemoglobinopathy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0929-8673
pubmed:author
pubmed:issnType
Print
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2903-9
pubmed:dateRevised
2007-2-12
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Haemoglobinopathy in pregnancy: diagnosis and treatment.
pubmed:affiliation
Perinatal Physiology Research Unit, Department of Obstetrics & Gynaecology, Zurich University Hospital, Switzerland. alexander.krafft@usz.ch
pubmed:publicationType
Journal Article, Review, Case Reports, Research Support, Non-U.S. Gov't